

STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL

USAN (JK-65)	CILGAVIMAB
PRONUNCIATION	sil gav' i mab
THERAPEUTIC CLAIM	Treatment and prevention of SARS-CoV-2 infection

CHEMICAL NAMES

1. Immunoglobulin G1 [248-threonine,249-methionine,316-tyrosine,318-threonine,320-glutamic acid], anti-(severe acute respiratory syndrome coronavirus 2 spike glycoprotein receptor-binding domain) (human monoclonal AZD1061 γ 1-chain), disulfide with human monoclonal AZD1061 κ -chain, dimer (Source: CAS)
2. Immunoglobulin G1-kappa, anti-[*Homo sapiens* severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike (S) protein, receptor binding domain (RBD)], *Homo sapiens* monoclonal antibody; gamma1 heavy chain *Homo sapiens* (1-461) [VH (*Homo sapiens* IGHV3-15*01 (96.0%) -(IGHD) - IGHJ4*01 (100%)) CDR-IMGT [8.10.22] (26-33.51-60.99-120) (1-131) -*Homo sapiens* IGHG1*03 G1m3, nG1m1, G1v21 CH2 Y15.1, T16, E18, G1v39 CH2 F1.3, E1.2, S116 (CH1 R120 (228) (132-229), hinge 1-15 (230-244), CH2 L1.3>F (248), L1.2>E (249), M15.1>Y (266), S16>T (268), T18>E (270), P116>S (345) (245-354), CH3 E12 (370), M14 (372) (355-459), CHS (460-461)) (132-461)], (234-219')-disulfide with kappa light chain *Homo sapiens* (1'-219') [V-KAPPA (*Homo sapiens* IGKV4-1*01 (96.0%) -IGKJ4*01 (100%)) CDR-IMGT [12.3.8] (27-38.56-58.95-102) (1'-112') -*Homo sapiens* IGKC*01 (100%) Km3 A45.1 (158), V101 (196) (113'-219')]; dimer (240-240":243-243")-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, glycoform alfa (Source: WHO, pINN list 124)

STRUCTURAL FORMULA

Heavy chain					
EVQLVESGGG	LVKPGGSLRL	SCAASGFTFR	DVWMSWVRQA	PGKGLEWVGR	50
IKSKIDGGTT	DYAAPVKGRF	TISRDDSKNT	LYLQMNSLKT	EDTAVYYCTT	100
AGSYYYDTVG	PGLPEGKFDY	WGQTLVTVS	SASTKGPSVF	PLAPSSKSTS	150
GGTAALGCLV	KDYFPEPVTV	SWNSGALTSG	VHTFPAVLQS	SGLYSLSSVV	200
TVPSSSLGTQ	TYICNVNHKP	SNTKVDKRV	PKSCDKTHTC	PPCPAPEFEG	250
GPSVFLFPPK	PKDTLYITRE	PEVTCVVVDV	SHEDPEVKFN	WYVDGVEVHN	300
AKTKPREEQY	NSTYRVVSVL	TVLHQDWLNG	KEYKCKVSNK	ALPASIEKTI	350
SKAKGQPREP	QVYTLPPSRE	EMTKNQVSLT	CLVKGFYPSD	IAVEWESNGQ	400
PENNYKTPP	VLDSGGSFFL	YSKLTVDKSR	WQQGNVFSCS	VMHEALHNHY	450
TQKSLSLSPG	K				461
Light chain					
DIVMTQSPDS	LAVSLGERAT	INCKSSQSVL	YSSNNKNYLA	WYQQKPGQPP	50'
LLLMYWASTR	ESGVPDRFSG	SGSGAEFTLT	ISSLQAEDVA	IYYCQYYST	100'
LTFGGGTKVE	IKRTVAAPSV	FIFPPSDEQL	KSGTASVVCL	LNNFYPREAK	150'
VQWKVDNALQ	SGNSQESVTE	QDSKSTYSL	SSTLTLSKAD	YEKHKVYACE	200'
VTHQGLSSPV	TKSFNRGEC				220'

Disulfide bridges

22-98	22''-98''	23'-94'	23'''-94'''	130'-199'	139'''-199'''	158-214	159''-214''
234-219'	234''-219''	240-240''	243-243''	275-335	275''-335''	381-439	381''-439''

Glycosylation sites (N)

311	311''
-----	-------

MOLECULAR FORMULA	C ₆₆₂₆ H ₁₀₂₁₈ N ₁₇₅₀ O ₂₀₇₈ S ₄₄
MOLECULAR WEIGHT	149.1 kDa
TRADEMARK	None as yet
SPONSOR	AstraZeneca
CODE DESIGNATIONS	AZD1061, COV2-2130, 2130
<u>CAS</u> REGISTRY NUMBER	2420563-99-9
UNII	1KUR4BN70F
WHO NUMBER	11777

gbk